Garniglipt-D

Description

Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), causes blood glucose to be eliminated through the urine, potently reduce intravascular volume through osmotic diuresis and natriuresis. Impressive results of the landmark SGLT2 inhibitor trials have becoming a powerful adjunctive therapy for the management of people with diabetes and HF- ESC Heart Fail. 2019 Oct; 6(5): 927–935. An interesting observation was made in patients where vildagliptin was combined with insulin. In these patients, an insulin sparing effect was seen, but more interestingly, less hypoglycemia was observed. No direct explanation is available, but further exploration of this phenomenon is warranted because of great clinical importance.- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.